Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1115)	12/11/1998 12:53:00 AM
From: Rob Loney	Respond to of 1580

Zocor is stabilizing! This is not good news. Shareholders of Merck expect growth not ..holding on for dear life. With the recently presented AVERT trial, atorvastatin is set to consume more and more market share. You can't make up $$$ for market leaders like vasotec, mevacor and zocor, with what they're got in the pipeline.

To: Anthony Wong who wrote (1115)	12/11/1998 3:04:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1580

Merck Study Says Singulair Improves Glaxo Asthma Drug's Effect quote.bloomberg.com

To: Anthony Wong who wrote (1115)	12/21/1998 8:14:00 PM
From: Henry Niman	Respond to of 1580

Tomorrow's Circulation will have a review on the benefits of CP IIb/IIIa inhibitors like CNTO's Reopro, CORR's Integrelin, and MRK's Aggrastat on reducing death rate in heart attack patients. Details linked to Cardiovascular Section of New Therapeutics page at biocognizance.com